NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) on behalf of long-term stockholders following a class action complaint that was filed against Amylyx on July 1, 2025 with a Class Period from November 11, 2022 to November 8, 2023. Our investigation concerns whether the board of directors of Amylyx have breached their fiduciary duties to the company ...